Physician profile
Robert H Levine
NPI 1124003330
$5,621.13
in general payments reported to CMS, 2019-2025
34 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $335 · 2021: $510 · 2022: $643 · 2023: $796 · 2024: $1,004 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.55 | 2019-2025 | |
| Braintree Laboratories, INC. | $812.18 | 2019-2025 | Suflave, Sutab |
| Pfizer INC. | $472.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.12 | 2019-2024 | Trulance, Xifaxan |
| Boston Scientific Corporation | $326.25 | 2019-2023 | Compliance Endokit |
| Qol Medical, LLC | $301.66 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $252.25 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $246.05 | 2019-2025 | Entyvio |
| Celgene Corporation | $228.93 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $224.21 | 2019-2025 | |
| Genzyme Corporation | $212.47 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $201.03 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $136.96 | 2024-2025 | Zenpep |
| Ucb, INC. | $133.94 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $100.68 | 2021-2025 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94.70 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $88.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $62.98 | 2022-2023 | |
| Lilly USA, LLC | $46.68 | 2025 | Omvoh |
| Amgen INC. | $41.27 | 2023 | Amjevita |
| Redhill Biopharma INC. | $31.35 | 2021 | |
| Olympus America INC. | $27.61 | 2020 | |
| Ethicon US, LLC | $26.68 | 2019 | |
| Fresenius Kabi USA, LLC | $21.45 | 2023 | |
| Sandoz INC. | $18.51 | 2024 | Hyrimoz |
| Echosens North America, INC. | $18.29 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $16.93 | 2025 | |
| Alfasigma USA, INC. | $16.70 | 2020 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Novo Nordisk INC | $16.48 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $15.59 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.76 | 2019 | |
| Organon LLC | $12.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.